Catalent
- Advanced Therapies Europe
- Gold Sponsor
- CDMO/CMO services
- Gene Therapy
- Cell Therapy
- Contract Development and Manufacturing Organisation/Contract Manufacturing Organisation
)
At Catalent, we champion the missions that matter to help people live better and healthier lives. Every medicine, therapy and product that we help develop, manufacture and deliver is part of our commitment to put patients first in everything we do. We are a trusted partner because we are committed to an exceptional, high-quality experience. Our customers turn to us for tailored solutions to meet their needs as we work together to transform lives.
Address
Catalent Pharma Solutions200 Crossing Blvd. 7th FLoor
Bridgewater
New Jersey
08807
United States
Website
https://biologics.catalent.com/Contact Exhibitor
-
Breaking the Bottleneck: Solving Late-Stage AAV Challenges with Real World Commercial Experience
10 Feb 2026One of the biggest hurdles sponsors face is finding a CDMO with true commercial AAV experience—partners who have successfully taken them through global approvals into the commercial market.
1 Results
Stay ahead of the curve with curated content from across the advanced therapies industry. From breaking news and regulatory updates to expert interviews and event highlights.
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
-
)
As adeno-associated virus (AAV) remains the cornerstone of gene therapy, the question is no longer if it will scale globally, but how. -
)
Late-stage AAV success is less about bigger bioreactors and more about decisions that lock in supply, comparability, and cost. This session breaks down what teams overlook and how to plan for commerci ... -
)
In partnership with Buchanan Ingersoll & Rooney, this session provides a comprehensive overview of FDA responsibilities for cell therapy companies. Speakers detail how the Agency categorizes HCT/Ps; w ... -
)
This webinar examined how to scale gene-enabled cell therapies, with emphasis on allogeneic programs moving toward commercial manufacture. The panel covered regulatory strategy, comparability, manufac ...